2126 — JW (Cayman) Therapeutics Co Share News
0.000.00%
Last trade - 00:00- HK$625.09m
- HK$347.70m
- CNY283.65m
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License
Brief: JW (Cayman) Therapeutics Says Min Liu Appointed As Chairman Of Board
Brief: JW (Cayman) Therapeutics Posts H1 Net Income RMB -240.3 Million
Brief: JW (Cayman) Therapeutics Appoints Min Liu As CEO
Brief: JW (Cayman) Therapeutics Posts IFRS Revenue Of RMB173.9 Mln For Year
Brief: Jw (Cayman) Therapeutics Says NMPA Accepted Biological License Application For Carteyva
Brief: Jw (Cayman) Therapeutics Says Strategic Partnership With 2Seventy Bio, Inc
Brief: Jw (Cayman) Therapeutics Says Xin Fu Tendered Resignation As CFO
Brief: JW (Cayman) Therapeutics Announces Potential Further Strategic Partnership With 2Seventy Bio
Brief: 2Seventy Bio And JW Therapeutics Announce Intent To Expand Strategic Partnership To Accelerate The Research And Development Of T Cell-Based Immunotherapies & Autoimmune Therapies
Brief: Jw (Cayman) Therapeutics Receives Investigational New Drug Clearance From NMPA Of China
Brief: Jw Therapeutics Announces IND Approval For Trial Of Relma-Cel In Autoimmune Disease Patients
Brief: Jw (Cayman) Therapeutics Posts IFRS Revenue Rmb145.7 Mln For Year
Brief: Medigene Receives $3 Mln Milestone Payment From 2Seventy Bio
China's JW rises on licence deal with major shareholder
Brief: 2Seventy Bio And Jw Therapeutics Announce Strategic Partnership To Accelerate The Research And Development Of T Cell-Based Immunotherapies